JP2021503005A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021503005A5 JP2021503005A5 JP2020544380A JP2020544380A JP2021503005A5 JP 2021503005 A5 JP2021503005 A5 JP 2021503005A5 JP 2020544380 A JP2020544380 A JP 2020544380A JP 2020544380 A JP2020544380 A JP 2020544380A JP 2021503005 A5 JP2021503005 A5 JP 2021503005A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- alkyl
- compound
- formula
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 226
- 125000000217 alkyl group Chemical group 0.000 claims description 67
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 150000002367 halogens Chemical class 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 125000005647 linker group Chemical group 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 14
- -1 R 31 Chemical compound 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 102000035195 Peptidases Human genes 0.000 claims description 12
- 108091005804 Peptidases Proteins 0.000 claims description 12
- 230000008878 coupling Effects 0.000 claims description 12
- 238000010168 coupling process Methods 0.000 claims description 12
- 238000005859 coupling reaction Methods 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 125000002947 alkylene group Chemical group 0.000 claims description 11
- 230000004936 stimulating effect Effects 0.000 claims description 11
- 230000021615 conjugation Effects 0.000 claims description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 239000004365 Protease Substances 0.000 claims description 8
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 8
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 8
- 235000004279 alanine Nutrition 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000006850 spacer group Chemical group 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
- 229940000635 beta-alanine Drugs 0.000 claims description 7
- FBFJOZZTIXSPPR-UHFFFAOYSA-N 1-(4-aminobutyl)-2-(ethoxymethyl)imidazo[4,5-c]quinolin-4-amine Chemical group C1=CC=CC2=C(N(C(COCC)=N3)CCCCN)C3=C(N)N=C21 FBFJOZZTIXSPPR-UHFFFAOYSA-N 0.000 claims description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
- 229960003767 alanine Drugs 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
- 229960003136 leucine Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims description 5
- 230000005867 T cell response Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 235000019419 proteases Nutrition 0.000 claims description 5
- 229960004295 valine Drugs 0.000 claims description 5
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims description 4
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 claims description 4
- 102000004225 Cathepsin B Human genes 0.000 claims description 4
- 108090000712 Cathepsin B Proteins 0.000 claims description 4
- 102000005600 Cathepsins Human genes 0.000 claims description 4
- 108010084457 Cathepsins Proteins 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 101000661807 Homo sapiens Suppressor of tumorigenicity 14 protein Proteins 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 125000000732 arylene group Chemical group 0.000 claims description 4
- 108010055066 asparaginylendopeptidase Proteins 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 230000014759 maintenance of location Effects 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 235000019833 protease Nutrition 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 210000001163 endosome Anatomy 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 claims description 2
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 claims description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 150000001345 alkine derivatives Chemical class 0.000 claims description 2
- 125000002355 alkine group Chemical group 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 2
- 229920005605 branched copolymer Polymers 0.000 claims description 2
- 238000007385 chemical modification Methods 0.000 claims description 2
- 229960002173 citrulline Drugs 0.000 claims description 2
- 235000013477 citrulline Nutrition 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 230000016396 cytokine production Effects 0.000 claims description 2
- 239000000412 dendrimer Substances 0.000 claims description 2
- 229920000736 dendritic polymer Polymers 0.000 claims description 2
- 238000009826 distribution Methods 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 229960003104 ornithine Drugs 0.000 claims description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 210000004989 spleen cell Anatomy 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- KQANCXMGWADCEG-JEDNCBNOSA-N (2S)-2-amino-4-methylpentanoic acid 3-aminopropanoic acid Chemical compound NCCC(O)=O.CC(C)C[C@H](N)C(O)=O KQANCXMGWADCEG-JEDNCBNOSA-N 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 108010091175 Matriptase Proteins 0.000 claims 1
- 102100032452 Transmembrane protease serine 6 Human genes 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 210000003712 lysosome Anatomy 0.000 claims 1
- 230000001868 lysosomic effect Effects 0.000 claims 1
- 108010047374 matriptase 2 Proteins 0.000 claims 1
- 230000000704 physical effect Effects 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 125000005559 triazolylene group Chemical group 0.000 claims 1
- 0 CCCCCCCCCCCCCC(*Cc1ccc(C[n]2c(-c3ccccc3NC3NC(OCc(cc4)ccc4NC4*(C)C4)=O)c3nc2CCCC)cc1)=O Chemical compound CCCCCCCCCCCCCC(*Cc1ccc(C[n]2c(-c3ccccc3NC3NC(OCc(cc4)ccc4NC4*(C)C4)=O)c3nc2CCCC)cc1)=O 0.000 description 6
- 125000004958 1,4-naphthylene group Chemical group 0.000 description 2
- 125000005549 heteroarylene group Chemical group 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000006587 (C5-C10) heteroarylene group Chemical group 0.000 description 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 description 1
- 125000005450 2,3-difluoro-1,4-phenylene group Chemical group [H]C1=C([*:2])C(F)=C(F)C([*:1])=C1[H] 0.000 description 1
- 125000005732 2,6-difluoro-1,4-phenylene group Chemical group [H]C1=C(F)C([*:1])=C(F)C([H])=C1[*:2] 0.000 description 1
- 125000004959 2,6-naphthylene group Chemical group [H]C1=C([H])C2=C([H])C([*:1])=C([H])C([H])=C2C([H])=C1[*:2] 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102100029637 Tryptase beta-2 Human genes 0.000 description 1
- 101710134953 Tryptase beta-2 Proteins 0.000 description 1
- 101710186357 Tryptase-2 Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 230000008350 antigen-specific antibody response Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023071478A JP7760175B2 (ja) | 2017-11-14 | 2023-04-25 | Ｔｌｒ７／８アゴニスト化合物の切断可能なコンジュゲート、その調製方法および使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762586110P | 2017-11-14 | 2017-11-14 | |
| US62/586,110 | 2017-11-14 | ||
| PCT/US2018/060849 WO2019099412A1 (en) | 2017-11-14 | 2018-11-13 | Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023071478A Division JP7760175B2 (ja) | 2017-11-14 | 2023-04-25 | Ｔｌｒ７／８アゴニスト化合物の切断可能なコンジュゲート、その調製方法および使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021503005A JP2021503005A (ja) | 2021-02-04 |
| JP2021503005A5 true JP2021503005A5 (https=) | 2021-12-23 |
Family
ID=64607318
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544380A Pending JP2021503005A (ja) | 2017-11-14 | 2018-11-13 | Ｔｌｒ７／８アゴニスト化合物の切断可能なコンジュゲート、その調製方法および使用 |
| JP2023071478A Active JP7760175B2 (ja) | 2017-11-14 | 2023-04-25 | Ｔｌｒ７／８アゴニスト化合物の切断可能なコンジュゲート、その調製方法および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023071478A Active JP7760175B2 (ja) | 2017-11-14 | 2023-04-25 | Ｔｌｒ７／８アゴニスト化合物の切断可能なコンジュゲート、その調製方法および使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10722591B2 (https=) |
| EP (1) | EP3710059A1 (https=) |
| JP (2) | JP2021503005A (https=) |
| WO (1) | WO2019099412A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| ES2951817T3 (es) | 2017-08-22 | 2023-10-25 | Dynavax Tech Corp | Derivados de imidazoquinolina de cadena alquílica modificada como agonistas de TLR7/8 y usos de los mismos |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| JP7590354B2 (ja) | 2019-06-10 | 2024-11-26 | ストロ バイオファーマ インコーポレーテッド | 免疫調節物質抗体薬物コンジュゲートおよびその使用 |
| JP7706210B2 (ja) | 2019-06-10 | 2025-07-11 | ストロ バイオファーマ インコーポレーテッド | ５Ｈ－ピロロ［３，２－ｄ］ピリミジン－２，４－ジアミノ化合物およびその抗体コンジュゲート |
| CN114746420A (zh) * | 2019-06-17 | 2022-07-12 | 苏特罗生物制药公司 | 用于癌症治疗和诊断的作为Toll样受体（TLR）7/8激动剂的1-(4-(氨基甲基)苄基)-2-丁基-2H-吡唑并[3,4-c]喹啉-4-胺衍生物及相关化合物以及其抗体药物偶联物 |
| CA3151322A1 (en) * | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| JP7735291B2 (ja) | 2020-02-21 | 2025-09-08 | エーアールエス ファーマシューティカルズ、インコーポレイテッド | ネクチン－４抗体コンジュゲートおよびその使用 |
| EP4114417A4 (en) * | 2020-03-06 | 2024-08-14 | OD Therapeutics Limited | THERAPEUTIC AGENTS AND THEIR CONJUGATES |
| US12564630B2 (en) | 2020-05-05 | 2026-03-03 | Virovax Llc | Vaccine adjuvants |
| JP2023532304A (ja) | 2020-07-01 | 2023-07-27 | エーアールエス ファーマシューティカルズ オペレーションズ，インク． | 抗ａｓｇｒ１抗体コンジュゲートおよびその使用 |
| KR102804873B1 (ko) * | 2020-08-04 | 2025-05-14 | 프로지니어 주식회사 | 동력학적 제어가 가능한 아주번트를 포함하는 mRNA 백신 |
| JP7690221B2 (ja) * | 2020-08-04 | 2025-06-10 | プロジェニア インコーポレイテッド | 動力学的に作用するアジュバントアンサンブル |
| KR102946557B1 (ko) * | 2020-08-04 | 2026-04-01 | 프로지니어 주식회사 | 활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 기능성 약물의 결합체 및 그 용도 |
| KR102800598B1 (ko) * | 2020-08-04 | 2025-04-30 | 프로지니어 주식회사 | 동력학적으로 작용하는 아주번트 앙상블 |
| US20230346924A1 (en) * | 2020-08-04 | 2023-11-02 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
| US20230277525A1 (en) * | 2020-08-04 | 2023-09-07 | Progeneer Inc | Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof |
| CN112336852A (zh) * | 2020-10-14 | 2021-02-09 | 深圳大学 | 全细胞疫苗及其制备方法与应用 |
| BR112023015561A2 (pt) * | 2021-02-03 | 2023-11-14 | Univ Minnesota | Compostos imunoestimuiladores e conjugados |
| IL305355A (en) * | 2021-03-02 | 2023-10-01 | Univ New York State Res Found | TLR7 and TLR8 agonists for the treatment of cancer and/or infectious diseases |
| KR102917231B1 (ko) * | 2021-03-08 | 2026-01-26 | 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. | 항체 면역 작용제 접합체 및 이의 적용 |
| CN113967256B (zh) * | 2021-10-26 | 2022-09-30 | 山东大学 | 一种具有光热-化疗-免疫功能的纳米粒及其制备方法和应用 |
| CN119136795A (zh) * | 2021-11-10 | 2024-12-13 | 芝加哥大学 | 具有增强的疗效和降低的毒性的nfkb激活剂的作为佐剂的小分子免疫增强剂的缀合物 |
| CN117417429A (zh) * | 2022-07-18 | 2024-01-19 | 亚飞（上海）生物医药科技有限公司 | 肿瘤微环境激活的细胞因子及其应用 |
| WO2024118785A2 (en) | 2022-11-30 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Tlr7 agonists and antibody-drug-conjugates thereof |
| CN121311513A (zh) * | 2023-04-12 | 2026-01-09 | 住友制药株式会社 | 葡聚糖与tlr7激动剂的缀合物 |
| WO2025015586A1 (en) * | 2023-07-20 | 2025-01-23 | Canwell Biotech Limited | Drug conjugates of imidazoquinoline amine derivatives, compositions and methods thereof |
| WO2025240397A1 (en) * | 2024-05-14 | 2025-11-20 | The Research Foundation For The State University Of New York | Tlr7 and tlr8 agonists and antibody-drug congjugates for the treatment of cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| JPH09500128A (ja) | 1993-07-15 | 1997-01-07 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | イミダゾ〔４，５−ｃ〕ピリジン−４−アミン |
| JPH1180156A (ja) | 1997-09-04 | 1999-03-26 | Hokuriku Seiyaku Co Ltd | １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体 |
| UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
| US6180095B1 (en) | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| ATE340592T1 (de) | 1999-04-23 | 2006-10-15 | Alza Corp | Konjugate enthaltend eine spaltbare bindung zur anwendung in einem liposom |
| US7238368B2 (en) | 1999-04-23 | 2007-07-03 | Alza Corporation | Releasable linkage and compositions containing same |
| US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| DK1545597T3 (da) | 2002-08-15 | 2011-01-31 | 3M Innovative Properties Co | Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons |
| JP2006503068A (ja) | 2002-09-26 | 2006-01-26 | スリーエム イノベイティブ プロパティズ カンパニー | １ｈ−イミダゾダイマー |
| CA2510375A1 (en) | 2002-12-20 | 2004-07-15 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
| EP2572714A1 (en) | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
| JP2006517974A (ja) | 2003-02-13 | 2006-08-03 | スリーエム イノベイティブ プロパティズ カンパニー | Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物 |
| US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
| EP1615665A4 (en) | 2003-04-10 | 2010-10-06 | 3M Innovative Properties Co | DISTRIBUTION OF THE IMMUNE RESPONSE MODIFYING LINKS |
| US7799800B2 (en) | 2003-08-14 | 2010-09-21 | 3M Innovative Properties Company | Lipid-modified immune response modifiers |
| PT1687305E (pt) | 2003-11-21 | 2008-10-17 | Novartis Ag | Derivados de 1h-imidazoquinolina como inibidores de proteína quinase |
| US7884207B2 (en) | 2004-06-18 | 2011-02-08 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| WO2007079086A1 (en) | 2005-12-28 | 2007-07-12 | Coley Pharmaceutical Group, Inc. | Pyrazoloalkyl substituted imidazo ring compounds and methods |
| EP1988896A4 (en) | 2006-02-22 | 2011-07-27 | 3M Innovative Properties Co | CONJUGATES TO MODIFY IMMUNE REACTIONS |
| US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
| WO2013166110A1 (en) * | 2012-05-02 | 2013-11-07 | Yale University | Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms) |
| EP2674170B1 (en) | 2012-06-15 | 2014-11-19 | Invivogen | Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids |
| EP2732825B1 (en) * | 2012-11-19 | 2015-07-01 | Invivogen | Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist |
| WO2014113634A1 (en) | 2013-01-17 | 2014-07-24 | University Of Kansas | Toll-like receptor 2-agonistic lipopeptides, and method of making the same |
| EP2769738B1 (en) | 2013-02-22 | 2016-07-20 | Invivogen | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists |
| US10471139B2 (en) | 2013-08-15 | 2019-11-12 | The University Of Kansas | Toll-like receptor agonists |
| GB201321242D0 (en) | 2013-12-02 | 2014-01-15 | Immune Targeting Systems Its Ltd | Immunogenic compound |
| DK3092256T3 (da) * | 2014-01-10 | 2022-06-20 | Birdie Biopharmaceuticals Inc | Forbindelser og sammensætninger til immunterapi |
| ES2908150T3 (es) | 2014-05-01 | 2022-04-27 | Novartis Ag | Compuestos y composiciones como agonistas del receptor de tipo Toll 7 |
| GB201418004D0 (en) | 2014-10-10 | 2014-11-26 | Isis Innovation | Polymer adjuvant |
| WO2017044803A1 (en) * | 2015-09-09 | 2017-03-16 | The United States Of America, As Represented By The Secretary Department Of Health And Human Service | Expression vector delivery system and use thereof for inducing an immune response |
| EP3368092B9 (en) | 2015-10-29 | 2020-07-29 | Novartis AG | Antibody conjugates comprising toll-like receptor agonist |
| AU2017376460A1 (en) | 2016-12-13 | 2019-06-20 | Bolt Biotherapeutics, Inc. | Antibody adjuvant conjugates |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| US20180311334A1 (en) | 2017-04-29 | 2018-11-01 | Yale University | Compositions and Methods for Inducing an Immune Response |
| ES2951817T3 (es) | 2017-08-22 | 2023-10-25 | Dynavax Tech Corp | Derivados de imidazoquinolina de cadena alquílica modificada como agonistas de TLR7/8 y usos de los mismos |
-
2018
- 2018-11-13 US US16/190,010 patent/US10722591B2/en active Active
- 2018-11-13 WO PCT/US2018/060849 patent/WO2019099412A1/en not_active Ceased
- 2018-11-13 JP JP2020544380A patent/JP2021503005A/ja active Pending
- 2018-11-13 EP EP18815083.3A patent/EP3710059A1/en active Pending
-
2023
- 2023-04-25 JP JP2023071478A patent/JP7760175B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021503005A5 (https=) | ||
| US10722591B2 (en) | Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof | |
| Chen et al. | STING activator c-di-GMP-loaded mesoporous silica nanoparticles enhance immunotherapy against breast cancer | |
| CA2582668C (en) | Nanoparticles comprising antigens and adjuvants, and immunogenic structures | |
| Xia et al. | Low molecular weight heparin-coated and dendrimer-based core-shell nanoplatform with enhanced immune activation and multiple anti-metastatic effects for melanoma treatment | |
| EP2413964B1 (en) | Vaccine compositions and methods of use thereof | |
| Li et al. | Copolymer of poly (ethylene glycol) and poly (L-lysine) grafting polyethylenimine through a reducible disulfide linkage for siRNA delivery | |
| JP2011523669A (ja) | 生分解性金属キレート化ポリマーおよびワクチン | |
| KR20100129749A (ko) | 치료, 진단과 실험적 혼합물들의 운반을 위한 공학적으로 가변된 나노입자 및 치료용 관련 조성물 | |
| JPWO2017002979A1 (ja) | 薬剤送達用キャリア及びこれを含む組成物 | |
| JP2024016040A (ja) | 去勢抵抗性前立腺癌 | |
| Lu et al. | Folate-targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor activity and allergic potential | |
| CN113577255A (zh) | 肿瘤纳米疫苗、其制备方法及用途 | |
| CN111087465B (zh) | 一种针对密蛋白6的抗体偶联药物及应用 | |
| Yang et al. | Transformable prodrug nanoplatform via tumor microenvironment modulation and immune checkpoint blockade potentiates immunogenic cell death mediated cancer immunotherapy | |
| Kim et al. | Effective targeted gene delivery to dendritic cells via synergetic interaction of mannosylated lipid with DOPE and BCAT | |
| JP2002531531A (ja) | 循環している抗体を減少させるための方法および処方物 | |
| Daeg et al. | Bivalent peptide-and chelator-containing bioconjugates as toolbox components for personalized nanomedicine | |
| WO2003017938A2 (en) | Conjugates targeted to target receptors | |
| CN118108861A (zh) | 一种靶向ebna1特异性b细胞的嵌合抗原受体、car-t细胞及其应用 | |
| CN110339352A (zh) | 共组装表位疫苗及其应用 | |
| JP2025504688A (ja) | 腫瘍免疫療法 | |
| CN101623503B (zh) | 生存素与路易斯寡糖的复合物及其制备方法和应用 | |
| CN119367522B (zh) | 一种用于mRNA疫苗递送的自组装糖肽纳米颗粒的制备与应用 | |
| US20260091097A1 (en) | Combination treatment regimes for treating cancer |